Get the Stockscreener App
2.15
8.59%
0.17
Dogwood Therapeutics Inc stock is traded at $2.15, with a volume of 105.80K.
It is up +8.59% in the last 24 hours and up +50.35% over the past month.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
See More
Previous Close:
$1.98
Open:
$1.95
24h Volume:
105.80K
Relative Volume:
1.61
Market Cap:
$72.30M
Revenue:
-
Net Income/Loss:
$-28.32M
P/E Ratio:
-0.2028
EPS:
-10.6039
Net Cash Flow:
$-15.52M
1W Performance:
+19.11%
1M Performance:
+50.35%
6M Performance:
-29.97%
1Y Performance:
-56.30%
1-Day Range:
$1.831
$2.15
1-Week Range:
$1.73
$2.15
52-Week Range:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.15 | 64.74M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Pain drug trial enrolls 217 as Dogwood expects fall 2026 results - Stock Titan
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Stock News Today - tradingkey.com
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - MarketBeat
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - dars.gov.et
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:1.530|Chg%:+0.030 - TradingKey
Dogwood Therapeutics Market Sentiment - Benzinga España
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dogwood Therapeutics Inc (DWTX) Balance Sheet - TradingKey
Dogwood Therapeutics Inc (DWTX) Income Statement - TradingKey
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Net Loss Exceeds Consensus Expectations Amid Clinical DevelopmentFinal Results - dars.gov.et
TradingKey - TradingKey
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
Dogwood (DWTX) Reaches Enrollment Milestone in HAL-CINP Phase 2b Trial - GuruFocus
Dogwood Therapeutics enrolls 200 patients in pain treatment trial - Investing.com
Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
Enterprise value to revenue forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics (DWTX) Slips 1% as Shares Test Support Near $1.36Ratio Spread Trade - dars.gov.et
Dogwood Therapeutics (DWTX) Slips Modestly, Holds Above Key Support LevelBull Flag - dars.gov.et
Dogwood Therapeutics (DWTX) Edges Higher Amid Tight Trading RangeRSI Overbought Alerts - dars.gov.et
Dogwood Therapeutics (DWTX) Holds Steady at $1.42 – Key Levels in FocusBuffered ETF - dars.gov.et
Virios Therapeutics weighs strategic options as development focus remains on fibromyalgia - Ad-hoc-news.de
Dogwood Therapeutics (DWTX) Rises 4.35% as Stock Climbs Toward Resistance LevelThrowback Trade - dars.gov.et
Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Enterprise value to EBIT forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
DWTXDogwood Therapeutics Inc Latest SEC Filings - Finviz
Dogwood Therapeutics Names OrbiMed’s Iain Dukes Chair of Scientific Advisory Board - citybiz
Dogwood Therapeutics appoints Iain Dukes to lead advisory board - Investing.com
Dogwood Therapeutics appoints Iain Dukes to lead advisory board By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewswire
Dogwood Therapeutics, Inc.(NasdaqCM:DWTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell Microcap Index - marketscreener.com
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):